Kendalle Burlin O'Connell, Esq.’s Post

I dug into what's driving the pace of private #biotech M&A and found that the answer isn't as simple as a closed IPO window. Here's what experts say is behind the clip of acquisitions by pharma this year, with commentary from Naveed Siddiqi, Jonathan Norris, Carolyn Ng, Travis Murdoch, MD and Michael Cohen. https://lnkd.in/gtBvpt5u

The buzz coming out of #JPM25 is quite positive, with a lot of discussion focused on dealmaking in #biotech. Following a year in which many investors sat on the sidelines, 2025 is starting off with a flurry of announcements about early-development partnerships and acquisitions. Great to see! 🙋♀️Please note that this article may be behind a paywall, but non-subscribers can access a limited number of free articles per month. #ExecutiveSearch  

An interesting shift in the M&A and IPO market for biotech.

Many boards of private drug developers are electing to simultaneously seek an IPO and a buyout at a time when M&A is heating up and there’s been a slight uptick in public debuts. "In the first half of this year, the median upfront deal size for private buyouts climbed to $1 billion, which was “more than three times the annual average of the past six years,” according to HSBC. " #businessdevelopment #startup #M&A #VC #biotech https://lnkd.in/erDshjR7

Here's an afternoon or morning read for you biotech/synbio biz people: Baker McKenzie's Global Guide to IPOs for biotech (synbio) companies. It provides a detailed comparison of features and requirements for how you can: - Successfully prepare - Think ahead before filing - Act strategically towards an IPO in the biotech sector IPOs are still happening in the biotech/synbio startup world, even though we see major acquisitions by big pharmas that withhold lots of cash reserves. Biotech and pharma companies can access global finance hubs and capital through an initial public offerings (IPOs). In-house jurisdictions or cross-border ones can play their pivotal role. I hope you'll find this report as much insightful as I have.

🚀 Biotech Financing: A Glimpse of Hope Amidst the Storm 🚀 The biotech sector has faced tough financial headwinds, but there’s light at the end of the tunnel. Despite reduced venture capital and IPO activity, larger funding rounds and a surge in M&A show resilience. There are optimistic signals, such as larger funding rounds for established companies and increased mergers and acquisitions. Emerging fields like AI-driven drug discovery are gaining traction, signaling a potential rebound. The future looks cautiously optimistic for those navigating these challenging times. 🔗 Read more https://rdcu.be/dSPuQ #Biotech #Finance #Innovation #VentureCapital #DrugDiscovery #CRO #CNR #CNRResearch #ClinicalTrials #EuropeClinicalTrials

According to BioWorld News Biopharma financings hit $47B in Q1, marking second-highest quarter Biopharma firms amassed a total of $47.07 billion in the first quarter of 2024, the second-highest quarter recorded by BioWorld since 2011, trailing only behind $48.18 billion raised in 2Q20. This robust fundraising was driven by exceptional performances in IPOs, follow-ons and public/other financings, as well as sustained trends in venture capital raises. The amount marks a 118% increase from $21.62 billion raised in the fourth quarter of 2023 and a 257% rise from 1Q23’s $13.19 billion.

Dive into our Biopharma and Medtech Licensing and Venture Reports to uncover the latest trends in upfront cash, mergers, acquisitions, and more from the third quarter of 2024. https://lnkd.in/gX4ghdRw

Omnium’s vision is to help biotech companies beat the odds by helping them mitigate risks in both scientific and commercial operations.  Navigating the biopharma industry is challenging. Here are five critical areas new biopharma companies need to focus on for success:    ➡ Executing Vision: Define a clear roadmap to align your team and stay adaptable to industry changes.   ➡ Strategizing Marketing: Understand your target audience, differentiate from competitors, and craft compelling messages.   ➡ Fundraising: Secure resources, build investor relationships, and ensure financial stability for growth.   ➡ Product Launches: Meet regulatory requirements, plan effective market entry, and engage stakeholders.   ➡ Exit Strategies: Maximize value through mergers, acquisitions, or IPOs, and prepare for long-term success.   If you are in the process of executing any of the above, we are happy to support and lend expertise!  Reach out to us and let’s chat! #Biopharma #Startup #Strategy #CorporateDevelopment #Fundraising #ProductLaunch #ExitStrategy #biotech #biotechinnovation

Dealmaking in the life sciences sector comes with characteristics not typically seen in more traditional mergers and acquisitions (M&A). Deals often involve negotiating around complexities associated with both the unique nature of assets of life sciences companies and the unique industry ecosystem that brings these assets to life. Innovations—be they to drugs or medical equipment—can take years to develop and are not always guaranteed to succeed in the various clinical trial stages. These innovations can also involve multiple stakeholders from academic institutions, hospitals, startups, and established companies, creating a complex web of ownership issues, competing interests, and priorities. Check out this article by my colleague Laurie Burlingame for more information. #mllifesci #wearemorganlewis